Information Provided By:
Fly News Breaks for February 19, 2020
Feb 19, 2020 | 14:09 EDT
Piper Sandler analyst Matt O'Brien noted that Abbott (ABT) and Dexcom (DXCM) both announced this morning their agreements to integrate their next gen CGM systems into the Omnipod Horizon System being developed by Insulet (PODD). While both partnerships have been expected for some time, he still views the news as positive for Insulet. He also thinks the news is "another expected step toward a truly intraoperative environment which we believe will only accelerate growth of both pumps and CGM going forward," O'Brien tells investors. He has Overweight ratings on Insulet and Dexcom, with a $200 price target on Insulet shares, a $300 price target on Dexcom and a $70 price target on shares of Tandem Diabetes (TNDM), which he also rates Overweight.
News For PODD;DXCM;ABT;TNDM From the Last 2 Days
There are no results for your query PODD;DXCM;ABT;TNDM